Hartland, MI, United States of America

Chad Vanhuis

This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignee: Odyssey Therapeutics, Inc.. Active years: 2026.

USPTO Granted Patents = 1 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Chad Vanhuis: Innovator in Medical Research

Introduction

Chad Vanhuis is a notable inventor based in Hartland, MI (US). He has made significant contributions to the field of medical research, particularly in the development of inhibitors for RIPK2. His work focuses on addressing various health conditions through innovative pharmaceutical compositions.

Latest Patents

Chad Vanhuis holds a patent for "Inhibitors of RIPK2 and medical uses thereof." This patent relates to RIPK2 inhibitors represented by a specific structural formula. The disclosure further encompasses pharmaceutical compositions that include these inhibitors and outlines methods for treating conditions such as inflammatory diseases, autoimmune diseases, granulomatous disease, neurodegenerative disease, and cancer. He has 1 patent to his name.

Career Highlights

Chad is currently associated with Odyssey Therapeutics, Inc., where he continues to advance his research and development efforts. His work is pivotal in the quest for effective treatments for complex medical conditions.

Collaborations

Chad collaborates with esteemed colleagues, including Shifeng Pan and Dominik K Koelmel. Their combined expertise enhances the innovative potential of their research endeavors.

Conclusion

Chad Vanhuis exemplifies the spirit of innovation in the medical field through his groundbreaking work on RIPK2 inhibitors. His contributions are vital for the advancement of treatments for various diseases, showcasing the importance of research and collaboration in the pursuit of medical breakthroughs.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…